Table 2.
Factors Influencing Controlled Attenuation Parameter Values Using Univariate and Multivariate Linear Regression Analysis
| All patients | NAFLD | ALD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||
| Variable | Uni | Multi | Uni | Multi | Uni | Multi | ||||||
|
|
|
|
|
|
|
|||||||
| β | p | β | p | β | p | β | p | β | p | β | p | |
| Age | −0.9 | 0.001 | −0.07 | 0.788 | −0.9 | 0.006 | −0.2 | 0.429 | −0.6 | 0.284 | - | - |
| Regular exercise | −17.0 | 0.012 | −4.1 | 0.461 | −22.0 | 0.013 | −1.5 | 0.847 | −10.0 | 0.322 | - | - |
| BMI | 5.7 | <0.001 | 3.2 | <0.001 | 4.7 | <0.001 | 2.0 | 0.109 | 6.8 | <0.001 | 5.3 | <0.001 |
| LSM | 2.0 | 0.019 | 0.7 | 0.297 | 1.8 | 0.091 | 0.8 | 0.390 | 2.4 | 0.091 | 2.3 | 0.068 |
| Steatosis in US | 35.8 | <0.001 | 28.9 | <0.001 | 36.3 | <0.001 | 30.8 | <0.001 | 34.4 | <0.001 | 22.9 | 0.001 |
| PLT | 0.1 | 0.083 | −0.001 | 0.991 | 0.2 | 0.020 | 0.01 | 0.941 | −0.02 | 0.832 | - | - |
| PT INR | 31.4 | 0.403 | - | - | −44.7 | 0.595 | - | - | 63.0 | 0.123 | 246.2 | 0.173 |
| ALT | 0.4 | <0.001 | 0.03 | 0.768 | 0.3 | 0.013 | −0.05 | 0.728 | 0.4 | 0.009 | −0.1 | 0.372 |
| ALP | −0.2 | 0.313 | - | - | 0.07 | 0.775 | - | - | −0.8 | 0.010 | −0.2 | 0.463 |
| GGT | −0.01 | 0.913 | - | - | 0.2 | 0.062 | 0.1 | 0.185 | −0.02 | 0.782 | - | - |
| Alb | 36.0 | 0.008 | 12.3 | 0.286 | 20.7 | 0.255 | - | - | 51.8 | 0.011 | 18.6 | 0.335 |
| TC | 0.09 | 0.365 | - | - | 0.05 | 0.320 | - | - | −0.2 | 0.190 | −0.1 | 0.361 |
NAFLD, nonalcoholic fatty liver disease; ALD, alcoholic liver disease; uni, univariate linear regression analysis; multi, multivariate linear regression analysis; β, beta coefficient; BMI, body mass index; LSM, liver stiffness measurement; US, ultrasound; PLT, platelet; PT INR, prothrombin time international normalized ratio; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; Alb, albumin; TC, total cholesterol.